TrialAIDS (London, England)2013

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy.

Allison Martin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.